Stock AVIR ATEA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-01 EDT 		5-day change 1st Jan Change
3.85 USD +4.05% Intraday chart for Atea Pharmaceuticals, Inc. +4.05% +26.23%
03-27 Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients CI
02-28 Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
AQ
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
AQ
Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
CI
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Atea Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
AQ
Transcript : Atea Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM
Atea Pharmaceuticals Reports 'Positive' Results on Hepatitis C Virus, COVID Trials; Shares Jump After Hours
MT
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
AQ
Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19
CI
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Atea Pharmaceuticals Says Bemnifosbuvir, Ruzasvir Combination Results Show Promise to Treat Hepatitis C Virus
MT
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
AQ
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Transcript : Atea Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
AQ
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AVIR Stock
  4. News Atea Pharmaceuticals, Inc.